ImmunoGen, Inc. Announces Webcast of Presentation at Upcoming Investor
WALTHAM, Mass. -- May 3, 2013
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops
anticancer therapeutics using its Targeted Antibody Payload (TAP)
antibody-drug conjugate (ADC) technology, today announced that Gregory Perry,
Executive Vice President and Chief Financial Officer, will present at the
upcoming Credit Suisse Antibody Day in New York. The presentation is scheduled
for 2:00 pm ET on May 10, 2013.
This webcast will be accessible live through the “Investor Information”
section of the Company’s website, www.immunogen.com; a replay will be
available at the same location for approximately a week.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's TAP
technology uses a tumor-targeting monoclonal antibody to deliver one of
ImmunoGen's highly potent cancer-cell killing agents specifically to tumor
cells. Ten TAP compounds are now in the clinic, of which three are wholly
owned by the Company. The most advanced compound using ImmunoGen's TAP
technology, Kadcyla™, has been approved for marketing in the US and is
undergoing regulatory review in Europe and Japan; it is being commercialized
in the US by Genentech, a member of the Roche Group. More information about
ImmunoGen can be found at www.immunogen.com.
Kadcyla™ is a trademark of Genentech.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and Corporate Communications
The Yates Network
Barbara Yates, 781-258-6153
Press spacebar to pause and continue. Press esc to stop.